Skip to search formSkip to main contentSkip to account menu

BFM-78

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Cytarabinecisplatin/cyclophosphamide/etoposide protocol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1992
1992
Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group.
Acute myelogenous leukemia (AML) represents a heterogenous group of leukemias in adults as well as in children. The BFM group… 
1990
1990
Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83.
Acute myelogenous leukemia (AML) represents a heterogeneous group of leukemias. It is a rare disease in children, accounting for… 
1987
1987
The childhood AML studies BFM-78 and -83: treatment results and risk factor analysis.
Within the last 10 years the prognosis of childhood AML has been improved by more intensive combination chemotherapy and better… 
1986
1986
[Current results of cooperative AML therapy studies in children: BFM-78 and 83].
271 children with AML entered the cooperative studies BFM-78 (151 pat.) and BFM-83 (120 pat.) since Dec. 1, 1978. In the second… 
1986
1986
Aktuelle Ergebnisse der kooperativen AML-Therapiestudien bei Kindern: BFM-78 und -83*
Vor Beginn der zytostatischen Therapie sind insgesamt IO Kinder an Blutung und/oder Leukostase verstorben. Von den 261… 
1984
1984
[Acute myelogenous leukemia in children under 2 years of age: studies and treatment results in 23 children in the AML therapy study BFM-78].
23 out of 151 patients of the childhood AML study BFM-78 were less than two years of age at the time of diagnosis, 10 of them… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)